Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE

oleh: D. Mott, M. Herdman, A. Robinson, B. Rappe, S. Hilman, U. De Giorgi, S. Joniau, R. Bordonaro, S. Mallick, L-M. Dourthe, M. Mira Flores, J. Gumà, H. Payne, M. De Santis, B. Baron, A. Duran, A. Pranzo, A. Serikoff, M. Pavesi